Tayga Kaan Hilal

- Building the Sales Excellence and Commercial Capability Development Organization for whole Emerging Markets - Planning Pfizer Transitional Service Agreement Exits with local Sales Excellence Leads and shifting to Viatris platforms - Improving commercial capabilities for our field-force including omnichannel operations, sales and marketing services, CRM tools, and training - +100 people in the org. among all Emerging Markets with 40+ countries with active business, more than 2000 Client Facing Colleagues, 3.5 B USD Business

• Built a whole support line for Sales Force Effectiveness, CRM, Meetings&Events, Omnichannel Sales Excellence and Customer Engagement Programs from scratch in AfME, improved existing capabilities in Russia and Turkey • Analyzed all gaps for Day1 Readiness of Mylan & Upjohn Integration, fulfilled those gaps through contracted resources or through negotiation of Transitional Service Agreements with Pfizer • Developed Omni-Channel Capabilities and finalized Dashboard in Russia and Gulf empowering reps by 360 view customer data • Gave valuable input both to Business and Center of Excellence Leads on global&local platforms and possible risks

• Forming Retail Business Plan for Pfizer Russia Upjohn including all marketing and commercial strategies • Optimizing coverage and frequency of Field Force, through Pharmacy Chains segmentation • Creating volume and marketing contracts with Pharmacy Chains along with trade marketing options in collaboration with PWC as legal consultant and internal stakeholders (accounting, legal, compliance) • 2 Retail Marketing Managers, 2 Key Account Manager Leads and 12 KAMs, 110 Retail Reps • Transformed Retail Go-To Market Model from 110 Reps to 12 KAMs with excellent collaboration with pharmacy chains

• Forming sales strategies and leading Russia PEH Sales with 200 representatives and 20 RMs and 5 Sales Leads • 18% growth in 2018 vs 2017 on core portfolio • Optimization of business plan process in each region, further education of RMs and analytics based approach to business

-Setting the business plan for Central Russia for the promotion of 16 promo products in retail and HCP segments achieved 105% plan realization in 2016 with 23% Growth vs 2015 on core portfolio - 7 RMs as direct reports and 53 Representatives  - Successful Projects on new reports creation with BI, improvement of discipline on the field, coverage of HCPs based on HCP profitability, Targeting of Pharmacies based on Retail Portfolio and Cooperation with Regional MoHs for hospital and budget sales

• Led the Russian, Romanian, Kazakhstan and Turkey Tender Teams with active Stakeholder Mapping and Management, Legal Initiatives and Business Case Development and Approval • Led the Strategical Projects around Emerging Europe such as Local Production and Export Initiatives • Led the Export Project of Tender Markets in collaboration with global teams analyzing the feasibility of exporting Prevnar from Local Legal Entities to EURIT & AfME Countries • Led the Russian Tender Team for the At Risk Production Case and Different Bidding Options • Shaped the “Confidentiality Approval Steps” in collaboration with Global Legal and Market Access

As a Marketing Lead, I am responsible to give Marketing Support for CauCAR (Caucasus and Central Asia Region – Kazakhstan, Azerbaijan, Georgia, Kyrgzstan, Uzbekhstan, Turkmenstan) by working closely with country managers and marketing directors. My main duty is to develop cross regional projects with the help of Pfizer Turkey and Russia, such as Oncology Advisory Boards, CV and CNS Campaigns, and International Speaker Trainings. Here are some of the "1st", we achieved among the region: * 1st Presentation of CauCAR to whole Pfizer Emerging Markets, Specialty Team of Kazakhstan at Never Before Summit * 1st Advisory Board Meetings of the Region on Oncology, CV and Women’s Health, (Azerbaijan Team at Baku) * 1st Preceptorship of CauCAR for Oncology at Maslak Acıbadem Hospital * 1st Face to Face Training of CauCAR Oncologists by Oncology Medical Sr. Regional Director: (ACT Medical for Oncology Sophie Leyman at 1st Oncology Advisory Board) * 1st Face to Face ACT Workshop held in a local country by ACT Regional Brand Manager: (ACT Marketing for Lyrica Quentin De Bogman at 1st Lyrica CauCAR Workshop) * 1st CauCAR KOL to present about his country in an international congress: (Prof. Davranbek Arybzhanov from Kazakhstan on “Cancer Burden at CIS Countries” at NEMA Congress) * 1st Hemophilia Meeting of the Region, in collaboration with Turkish National Hemophilia Association * 1st Big and Bold Cycle Meeting as CauCAR (6 countries)

As a Marketing Lead, I was responsible for setting the Marketing and Sales strategies for both Transplantation and Endocrinology. My main duty on the Endocrinology Side was to successfully launch GoQuick, new form of Genotropin with the built-in cartridge. Having the first Ready-To-Use Pen in the Market, we managed to position our Ease of Use, with the help of readiness, to be able to differentiate a Growth Hormone Product, in a Growth Hormone Market, where all products’ ingredient is the same. To increase collaboration and personal touch with KOLs, we developed also a medical support website www.genomed.info , where our KOLs could directly ask online “new literatures, literature translations, congress posters, medical books, statistical analysis” , which directly contributed to our Pfizer Image, when competing with companies which have a much huger Endocrinology Portfolio. Through these strategies, a 4% MS increase was achieved in Genotropin MAT Sales, from 24% to 28%, a product which was constantly losing MS in the last 10 years.

As a Marketing Lead for Rapamune, I was responsible of re-launching Rapamune, setting both Marketing&Sales Strategies, working very closely with the sales team for effective Key Account Management. I have managed to take Rapamune from %2 MAT Unit Growth to %28 MAT Unit Growth in 6 months with right strategies both on marketing and sales side. With the help of financial success, I also managed to internally convince global colleagues to organize the International Transplantation Symposium of Pfizer first time in Turkey in April 2012, in which our KOLs will take place actively, working closely with international KOLs.

As a Product Manager of Prevenar 13, I was responsible of launching Prevenar 13 for the Turkish Market, setting marketing strategies and positioning Prevenar in the Private Market. Prevenar 7 was already at the National Immunization Program of Turkey, Prevenar 13 had the chance to generate sales in the private market. My main duties were making sure Prevenar 13 is launched successfully, developing and improving KOL relationships, which also carry an important role to stabilize NIP position for Prevenar 7 and 13, growing the Vaccines Market and protecting Market Share against Synflorix of GSK.

As a project manager, I was involved in in-licensing new products, originals and generics. For this, I searched databases Adis Insight and IDDB for molecules in Phase III, and contacted these companies locally for the local marketing rights. I looked for opportunities inside Turkish Market to in-license products from already existing companies in Turkey, which are already registered. I also looked for developing partnerships with generic companies such as Chemo, Hetero, Lupin. Another duty of mine, was to constantly check P&Ls for deals such as Aurobindo, Olmetec Deal with Daichi Sankyo and Spiriva Deal with Boehringer Ingelheim. In all these processes, I managed to improve my abilities in forecasting sales, P&L establishing, deal making&improving and generic partnerships and patent checks.

As a project manager, I was involved in the strategic integration process of Wyeth and Pfizer, the new design of the sales force teams, new organization in business units and P&L’s of each business unit. I was also responsible to both explain Wyeth products and their competition both from a marketing and medical point of view. I also lead the yearly budget, target and long range forecast processes and had the opportunity to forecast sales for each promoted product of Pfizer.

As an intern I was responsible of preparing Merrill Lynch’ s weekly ,monthly and quarterly reports ( like balance sheet, foreign currency position, interest risk, market risk, foreign currency risk ) for the Turkish National Bank, Capital Markets Board, Banking Regulation-Supervision Agency and Union of Banks, plus helping Deloitte through the solo and consolidated audit for ML Investment Bank and ML Securities Brokerage Firm

(products: Scotch, Scotchguard ,Nexcare ,Command ) As an intern I was working with advertisement agencies for the new designs of handouts, and fliers. I arranged Scotchbrite’s sponsorship for my university’s sports festival. I also was involved in other daily activities like checking the sample locker, sending samples to new distributors , markets, and restaurants, preparing the yearly forecast tables, or going to field to check markets, shelves.

the daily mutual fund prices to Citibank’s bank branches, obtaining the data of customers who have attended the overnight interest campaign, checking the interest rates of customers on this data, correcting errors in interest rates by consulting my supervisors, and informing the bank branch to do the necessary correction.

As an intern I was responsible of finding new models, ideas, products and services, throughout Internet and published material in order to improve the present and new facilities.